References
- LassenMRRaskobGEGallusAPineoGChenDPortmanRJApixaban or enoxaparin for thromboprophylaxis after knee replacementN Engl J Med200936159460419657123
- LassenMRRaskobGEGallusAPineoGChenDHornickPApixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trialLancet201037580781520206776
- LassenMRGallusARaskobGEPineoGChenDRamirezLMApixaban versus enoxaparin for thromboprophylaxis after hip replacementN Engl J Med20103632487249821175312
- GrangerCBAlexanderJHMcMurrayJJApixaban versus warfarin in patients with atrial fibrillationN Engl J Med201136598199221870978
- ConnollySJEikelboomJJoynerCApixaban in patients with atrial fibrillationN Engl J Med201136480681721309657
- AgnelliGBullerHRCohenAApixaban for extended treatment of venous thromboembolismN Engl J Med201336869970823216615
- AgnelliGBullerHRCohenAOral apixaban for the treatment of acute venous thromboembolismN Engl J Med201336979980823808982
- ShimadaYJNakraNCFoxJTKaneiYRelation of race (Asian, African-American, European-American, and Hispanic) to activated clotting time after weight-adjusted bolus of heparin during percutaneous coronary interventionAm J Cardiol201010562963220185008
- YuenEGueorguievaIWiseSSoonDAaronsLEthnic differences in the population pharmacokinetics and pharmacodynamics of warfarinJ Pharmacokinet Pharmacodyn20103732419941044
- LeeSCNgSSOldenburgJInterethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian populationClin Pharmacol Ther20067919720516513444
- International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human UseICH Harmonised Tripartite Guideline: Ethnic factors in the acceptability of foreign clinical data – E5 (R1)1998 Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E5_R1/Step4/E5_R1__Guideline.pdfAccessed October 3, 2013
- BarrettYCWangZFrostCShenkerAClinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assayThromb Haemost20101041263127120978714
- FrostCNepalSBarrettYLaCretaFEffects of age and gender on the single-dose pharmacokinetics (PK) and pharmacodynamics (PD) of apixabanJ Thromb Haemost20097PP-MO-407
- RaghavanNFrostCEYuZApixaban metabolism and pharmacokinetics after oral administration to humansDrug Metab Dispos200937748118832478
- FrostCWangJNepalSApixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjectsBr J Clin Pharmacol20137547648722759198
- FrostCNepalSWangJSafety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjectsBr J Clin Pharmacol Epub342013
- ZhangDFrostCEHeKInvestigating the enteroenteric recirculation of apixaban, a factor Xa inhibitor: administration of activated charcoal to bile duct-cannulated rats and dogs receiving an intravenous dose and use of drug transporter knockout ratsDrug Metab Dispos20134190691523386703
- FrostCYuZNepalSApixaban, a direct factor Xa inhibitor: single-dose pharmacokinetics and pharmacodynamics of an intravenous formulation [abstract 148]J Clin Pharmacol2008481132
- WangLZhangDRaghavanNIn vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studiesDrug Metab Dispos20103844845819940026
- ZhangDHeKRaghavanNComparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humansDrug Metab Dispos2009371738174819420130
- ZhangDHeKHerbstJCharacterization of transporters involved in distribution and disposition of apixabanDrug Metab Dispos20134182783523382458
- YamahiraNImaiYWastallPA placebo-controlled, ascending multiple-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of apixaban in healthy Japanese subjects (A637)Can J Clin Pharmacol200815e719
- YuZNepalSBragatAShenkerAFrostCSingle dose apixaban pharmacokinetics and pharmacodynamics in healthy male Japanese and Caucasian subjects (A647)Can J Clin Pharmacol200815e724
- ZhangDHeKRaghavanNMetabolism, pharmacokinetics and pharmacodynamics of the factor Xa inhibitor apixaban in rabbitsJ Thromb Thrombolysis201029708019851712
- BarrettYCWangJSongYA randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjectsThromb Haemost201210791692422398784